Eli Lilly and Company has announced a $4.5-billion investment to create the Lilly Medicine Foundry, a new center for advanced manufacturing and drug development.  

The facility will give Lilly the ability to research new ways of producing medicines while also scaling up manufacturing of medicines for clinical trials. The facility will be located in Lebanon, Indiana, and will expand the company’s total investment there to more than $13 billion. The site’s location in Lebanon will support collaboration with Lilly Research Laboratories’ teams in Indianapolis and Lilly’s manufacturing sites in Lebanon, both in Indiana.  

The new facility will enable production of various molecular therapies, including drug substances for small molecules, biologics, and nucleic acid therapies. New technologies developed at the facility will be transferred to Lilly’s other manufacturing sites for full-scale production. Once fully operational, the facility is expected to add 400 full-time jobs, including  engineers, scientists, operations personnel, and lab technicians. 

This new facility will add to Lilly’s previous manufacturing commitments in Lebanon: 

• In May 2022, Lilly announced plans to invest $2.1 billion in two new manufacturing sites in Lebanon to expand its network for active pharmaceutical ingredients (APIs) and new modalities, such as genetic medicines. 

• In April 2023, Lilly broke ground on these facilities and announced an additional $1.6 billion investment at the site.  

• In May 2024, Lilly announced an additional $5.3 billion commitment to enhance capacity to manufacture APIs for its latest diabetes and obesity medicines. 

Source: Eli Lilly and Company